Compare ARK Genomic Revolution ETF (ARKG) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Campbell Soup Co. — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Campbell Soup Co. trades at $22.15 (market cap $6.58B). The key difference: Campbell Soup Co. pays a 7.07% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Campbell Soup Co. nearer its low. Which is the better fit depends on your goals.
| ARKG | CPB | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $34.03 |
52-Week Low | $23.09 | $20.00 |
Market Cap | — | $6.58B |
Enterprise Value | — | $13.19B |
Dividend Yield | — | 7.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Campbell's (CPB) trades at $22.07, up 2.79% today, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation metrics with a P/E of 10.82 and P/S of 0.67, but profitability remains modest with a 6.12% net margin. Recent news highlights cost-cutting efforts and a 7% dividend yield, though sales declines and margin pressures persist.
Outlook is cautious due to weak analyst consensus (only 3.45% buy ratings) and structural margin challenges. The stock offers value and income potential but faces headwinds from inflation and competitive pressures. Risks include execution on cost savings and consumer demand volatility, with the consensus price target at $20.00 suggesting limited upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
